The treatment of chronic myeloid leukaemia--much still to be achieved.

Abstract

Journal of Internal MedicineVolume 235, Issue 4 p. 289-291 Free Access The treatment of chronic myeloid leukaemia—much still to be achieved Professor J. M. Goldman, Corresponding Author Professor J. M. Goldman Professor of Leukaemia Biology LRF Leukaemia Unit Royal Postgraduate Medical School London, UKHaematology Department, Royal Postgraduate Medical School, Ducane Road, London W12 ONN, UKSearch for more papers by this author Professor J. M. Goldman, Corresponding Author Professor J. M. Goldman Professor of Leukaemia Biology LRF Leukaemia Unit Royal Postgraduate Medical School London, UKHaematology Department, Royal Postgraduate Medical School, Ducane Road, London W12 ONN, UKSearch for more papers by this author First published: April 1994 https://doi.org/10.1111/j.1365-2796.1994.tb01078.xCitations: 1AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. Blood 1993: 82: 398– 407. 2 Talpaz M, McCredie KB, Mavligit GM, Gutterman JU. Leukocyte interferon induced-myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983: 62: 689– 92. 3 Baccarani M. Tura S for the Italian Cooperative Study Group on Chronic myeloid Leukemia. Progress in treatment of chronic myeloid leukemia: interferon versus conventional chemotherapy. New Engl J Med 1993 (in press). 4 Lee M-S, Kantarjian H, Talpaz M, Freireich EJ, Deisseroth A, Trujillo JM, Stass SA. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood 1992: 79: 1920– 23. 5 Goldman JM, Biggs JC, Bortin MM, Champlin RE, Gluckman E, Hoffman RG et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann Intern Med 1988: 108: 806– 14. 6 McGlave P, Bartsch G, Anasetti C, Ash R, Beatty P, Gajewski J, Kernan NA, Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood 1993: 81: 543– 50. 7 Beatty PG, Hansen JA, Longton GM, Thomas ED, Sanders JE, Martin PJ et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematological malignancies. Transplantation 1991: 51: 443– 7. 8 Hoyle C, Gray R, Goldman JM for the Hammersmith BMT Team. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: a comparison of complications in the first two years. Annul Intern Med 1993: 119: 207– 14. 9 Kaminski E, Hows J, Man S, Brookes P, Mackinnon S, Hughes T, Avakian O, Goldman JM, Batchelor JR. Prediction of graft-versus-host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. Transplantation 1989: 48: 608– 13. 10 Theobald M, Nierle T, Bunjes J, Arnold R, Heimpel H. Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. New Engl J Med 1992: 327: 1613– 17. 11 Schwarer AP, Jiang YZ. Brookes PA, Barrett AJ, Batchelor JR, Goldman JM, Lechler RI. The frequency of alloreactive helper T-cell precursors in donor blood predicts graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Lancet 1993: 341: 203– 5. 12 Hoyle C, Gray R, Goldman JM et al. Autografting for patients with CML in chronic phase–an update. Brit J Haematol (In press). 13 Barnett MJ, Eaves CJ, Phillips GL, Kalousek DK, Klingemann HG, Lansdorp PM, Reece DE, Sheperd JD, Shaw GJ, Eaves AC. Successful autografting in chronic myeloid leukaemia after maintenance in culture. Bone Marrow Transplant 1989: 4: 345– 51. 14 Carella AM, Pollicardo N, Raffo NR, Podesta M, Carlier P, Valboniesi M, Vitale V, Gallamini A. Intensive conventional chemotherapy can lead to a precocious overshoot of cyto-genetically normal blood stem cells (BSC) in chronic myeloid leukemia and acute lymphoblastic leukemia. Leukemia 1992: 6 (Suppl. 4): 120– 23. Citing Literature Volume235, Issue4April 1994Pages 289-291 ReferencesRelatedInformation